RESUMO
Real-world data (RWD) could be a new way to evaluate the safety and efficacy of post-marketing drugs, while there is no common method for how to use RWD for drug evaluation. In this paper, we present a framework for real-world drug evaluation based on electronic medical record (EHR) data. We designed a data model customized for post-marketing drug evaluation and a unified post-marketing drug evaluation pipeline. The proposed framework can be applied to drug evaluations with different study paradigms for different purposes by flexible use of the proposed data model and pipeline. A prototype system has been developed according to the framework. Real-world EHRs in a tertiary hospital in China between 2010 and 2020 were converted to the proposed data model, and as a test case, we conducted a research on the risk of allergic reactions to cefodizime and ceftriaxone using the prototype system.
Assuntos
Ceftriaxona , Registros Eletrônicos de Saúde , Avaliação de Medicamentos , China , MarketingRESUMO
Ex vivo patient-derived tumor slices (PDTS) are currently limited by short-term viability in culture. Here, we show how bioengineered hydrogels enable the identification of key matrix parameters that significantly enhance PDTS viability compared to conventional culture systems. As demonstrated using single-cell RNA sequencing and high-dimensional flow cytometry, hydrogel-embedded PDTS tightly preserved cancer, cancer-associated fibroblast, and various immune cell populations and subpopulations in the corresponding original tumor. Cell-cell communication networks within the tumor microenvironment, including immune checkpoint ligand-receptor interactions, were also maintained. Remarkably, our results from a co-clinical trial suggest hydrogel-embedded PDTS may predict sensitivity to immune checkpoint inhibitors (ICIs) in head and neck cancer patients. Further, we show how these longer term-cultured tumor explants uniquely enable the sampling and detection of temporal evolution in molecular readouts when treated with ICIs. By preserving the compositional heterogeneity and complexity of patient tumors, hydrogel-embedded PDTS provide a valuable tool to facilitate experiments targeting the tumor microenvironment.
Assuntos
Neoplasias de Cabeça e Pescoço , Hidrogéis , Humanos , Hidrogéis/farmacologia , Avaliação de Medicamentos , Microambiente TumoralRESUMO
INTRODUCTION: While crizotinib and entrectinib have been approved to treat ROS1 fusion-positive (ROS1+) non-small-cell lung cancer (NSCLC), unmet needs remain. These unmet needs include treatment options for patients with resistance mutations and efficacious options even in the presence of brain metastasis while simultaneously avoiding unwanted neurological side effects. AREAS COVERED: Taletrectinib was designed to: improve efficacy; overcome resistance to first-generation ROS1 inhibitors; and address central nervous system penetration while conferring fewer neurological adverse events. All of these features are demonstrated and supported by data from the phase I and the regional phase II TRUST-I clinical trial. Here, we describe the preclinical and clinical characteristics of taletrectinib and evaluate the data from phase I and II studies and review the rationale and design of TRUST-II, a global phase II study of taletrectinib, which is enrolling patients in North America, Europe, and Asia. EXPERT OPINION: Taltrectinib has the potential to improve PFS based on its greater potency against ROS1+ tumors and high CNS penetration. By selectively inhibiting ROS1 wild-type and its resistant mutations over TRKB, taltrectinib has a better safety profile with minimal CNS-related AEs compared to other ROS1+ inhibitors.
Assuntos
Carcinoma Pulmonar de Células não Pequenas , Imidazóis , Neoplasias Pulmonares , Piridazinas , Humanos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/genética , Carcinoma Pulmonar de Células não Pequenas/patologia , Neoplasias Pulmonares/patologia , Espécies Reativas de Oxigênio , Proteínas Tirosina Quinases/genética , Avaliação de Medicamentos , Inibidores de Proteínas Quinases/efeitos adversos , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas/uso terapêutico , Ensaios Clínicos Fase II como AssuntoRESUMO
Human induced pluripotent stem cell (hiPSC)-derived cardiac organoids (COs) have shown great potential in modelling human heart development and cardiovascular diseases, a leading cause of global death. However, several limitations such as low reproducibility, limited vascularization and difficulty in formation of cardiac chamber were yet to be overcome. We established a new method for robust generation of COs, via combination of methodologies of hiPSC-derived vascular spheres and directly differentiated cardiomyocytes from hiPSCs, and investigated the potential application of human COs in cardiac injury modelling and drug evaluation. The human COs we built displayed a vascularized and chamber-like structure, and hence were named vaschamcardioids (vcCOs). These vcCOs exhibited approximately 90% spontaneous beating ratio. Single-cell transcriptomics identified a total of six cell types in the vcCOs, including cardiomyocytes, cardiac precursor cells, endothelial cells, fibroblasts, etc. We successfully recaptured the processes of cardiac injury and fibrosis in vivo on vcCOs, and showed that the FDA-approved medication captopril significantly attenuated cardiac injury-induced fibrosis and functional disorders. In addition, the human vcCOs exhibited an obvious drug toxicity reaction to doxorubicin in a dose-dependent manner. We developed a three-step method for robust generation of chamber-like and vascularized complex vcCOs, and our data suggested that vcCOs might become a useful model for understanding pathophysiological mechanisms of cardiovascular diseases, developing intervention strategies and screening drugs.
Assuntos
Doxorrubicina , Células-Tronco Pluripotentes Induzidas , Miócitos Cardíacos , Organoides , Humanos , Organoides/efeitos dos fármacos , Organoides/metabolismo , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/citologia , Miócitos Cardíacos/metabolismo , Células-Tronco Pluripotentes Induzidas/citologia , Células-Tronco Pluripotentes Induzidas/efeitos dos fármacos , Células-Tronco Pluripotentes Induzidas/metabolismo , Doxorrubicina/farmacologia , Cardiopatias/patologia , Cardiopatias/tratamento farmacológico , Diferenciação Celular/efeitos dos fármacos , Captopril/farmacologia , Animais , Células Cultivadas , Avaliação de Medicamentos/métodosRESUMO
BACKGROUND: Risankizumab and guselkumab, inhibitors of the interleukin (IL)-23 p19 subunit, are approved for treatment of adult patients with moderate-to-severe plaque psoriasis, and both have shown superiority over placebo in randomised clinical trials. Both agents have also shown superiority to the IL-17 inhibitor secukinumab at different timepoints. We investigated the efficacy and safety of the IL-23 p19 inhibitor mirikizumab versus placebo and secukinumab for patients with moderate-to-severe plaque psoriasis. METHODS: OASIS-2 was a phase 3, multicentre, randomised, double-blind trial. We recruited participants aged at least 18 years who had a confirmed diagnosis of chronic plaque psoriasis for at least 6 months before baseline that involved at least 10% of body surface area (BSA), an absolute Psoriasis Area and Severity Index (PASI) score of at least 12, and a Static Physician's Global Assessment (sPGA) score of at least 3 at both the screening and baseline visits. We excluded patients who had an uncontrolled or unstable health condition at screening. We randomly assigned patients (4:4:4:1) to receive 250 mg mirikizumab every 4 weeks for 16 weeks (induction) then every 8 weeks from week 16 to week 52 (maintenance); 250 mg mirikizumab every 4 weeks for 16 weeks, then 125 mg mirikizumab every 8 weeks from week 16 to 52; 300 mg secukinumab once weekly up to week 4, then every 4 weeks thereafter; or placebo every 4 weeks for 16 weeks, followed by 250 mg mirikizumab every 4 weeks from week 16 to 32 and then every 8 weeks from week 32 to 52. The primary outcome was superiority of mirikizumab (250 mg induction dose) versus placebo at week 16, assessed as the proportion of patients with an sPGA score of 0 or 1 with an improvement from baseline of at least 2 points, and the proportion of patients with at least 90% improvement from baseline in PASI score (PASI 90), in the intention-to-treat-population. We assessed safety in all randomly assigned participants who received at least one dose of mirikizumab until week 16 (induction safety population) and all randomly assigned participants who received at least one dose of mirikizumab or secukinumab until week 52 (active treatment safety population). This trial is registered at ClinicalTrials.gov, NCT03535194, and is completed. FINDINGS: Between June 26, 2018, and April 2, 2019, we screened 1738 participants, of whom 1465 (84·3%) were enrolled. The mean age of participants was 46·0 years (SD 13·8), 1000 (68·3%) were men, 465 (31·7%) were women, and 1195 (81·6%) were White. Participants were randomly assigned to receive mirikizumab 250 mg for induction and maintenance (n=454 [31·0%]), mirikizumab 250 mg for induction and 125 mg for maintenance (n=451 [30·8%]), secukinumab 300 mg (n=448 [30·6%]), or placebo followed by mirikizumab (n=112 [7·6%]). Baseline characteristics were similar across treatment groups. At week 16, 721 (79·7% [95% CI 77·0-82·3]) of 905 participants in the mirikizumab 250 mg induction groups had an sPGA score of 0 or 1 versus seven (6·3% [1·8-10·7]) of 112 participants in the placebo group (p<0·0001 for superiority). At week 16, 673 (74·4% [71·5-77·2]) of 905 participants in the mirikizumab groups had PASI 90 compared with seven (6·3% [1.8-10.7]) in the placebo group (p<0·0001 for superiority). Treatment-emergent adverse events were reported with similar frequency across treatment groups during weeks 0-52. Four major adverse cardiovascular events were reported in the mirikizumab groups versus none in the placebo and secukinumab groups up to week 16, with one fatal acute myocardial infarction in a patient treated with mirikizumab, which the investigator considered to be related to the study drug. INTERPRETATION: This trial showed superiority of mirikizumab at a dose of 250 mg over placebo in patients with moderate-to-severe plaque psoriasis, with a safety profile consistent with that of the IL-23 class. The study sponsor is not pursuing licensing of mirikizumab in this patient population because of a reprioritised development strategy with a focus on gastrointestinal-related indications. FUNDING: Eli Lilly and Company.
Assuntos
Anticorpos Monoclonais Humanizados , Interleucina-23 , Adulto , Masculino , Humanos , Feminino , Adolescente , Pessoa de Meia-Idade , Método Duplo-Cego , Superfície Corporal , Avaliação de MedicamentosRESUMO
Proponemos el presente estudio para la identifica-ción del fenómeno "Diagnóstico Lastre Generado por Medicamentos" (DLGM), que es la traducción farmacéutica de la interpretación médica de un problema de salud generado por medicamentos y atribuido a causas clínicas con la consiguiente pérdida de identidad que limita su identificación y manejo. No habrá mejoría de la enfermedad si no se corrige la causa del problema, por lo que cabe esperar un empeoramiento y persistencia de la enfermedad marcados por el fracaso farmacote-rapéutico, convirtiendo el problema de salud en un verdadero lastre para los pacientes a la espera de ser identificado.La propuesta de un algoritmo de caracterización del problema como herramienta de cribado se ha aplicado a 10 pacientes en el servicio de segui-miento farmacoterapéutico, confirmando la sospe-cha de DLGM, y demostrando que las reacciones adversas a medicamentos habían adquirido la identidad de una enfermedad. Un DLGM podría defi-nirse como la entidad que surge al diagnosticar una enfermedad sobre un resultado negativo asociado al uso del medicamento y que, por tanto, no recibe el tratamiento adecuado.La identificación del fenómeno DLGM permite detectar muchos resultados negativos asociados a la medicación (RNM) y contribuye a su adecuado tratamiento.No identificar un DLGM complica el estado clínico del paciente y limita su recuperación. (AU)
The present study was proposed for the identifica-tion the phenomenon "Diagnosis load Generated by Medications" (DLGM), which is the pharmaceutical translation to the medical interpretation of a health problem generated by medications and attributed to clinical causes with the consequent loss of iden-tity limiting its identification and handling. There will be no improvement of the desease if the cause of the problem is not corrected, so worsening and persistence of the disease marked by pharmaco-therapeutic failure is to be expected, making the health problem a real burden for patients to waiting to be identified.The proposal of an algorithm characterising the problem as a screening tool has been applied to 10 patients in the pharmacotherapeutic monitoring service, confirming the suspicion of DLGM, and demonstrating that adverse drugs reactions had acquired the identity of a disease. DLGM could be defined as the entity that arises from diagnosing a disease on a negative results associated to medici-ne use and that therefore does not receive adequa-te treatment.The identification of the DLGM phenomenon allows the detection of many Negative Outcomes Relea-ted to Mediccines (NOMs) and contributes to their adequate treatment.Not identifying DLGM complicates the clinical con-dition of the patient and his/her recovery. (AU)
Assuntos
Humanos , Resultados Negativos , Combinação de Medicamentos , Avaliação de Medicamentos , Incompatibilidade de MedicamentosRESUMO
Objetivo: Avaliar interações medicamentosas (IM), em que os riscos se so- brepõem aos benefícios (nível I) ou os benefícios se sobrepõem aos riscos (nível II); a partir da análise retrospectiva de prescrições médicas em um Hospital Universitário no estado de São Paulo, Brasil. Métodos: Foram analisadas 19762 prescrições médicas des- tinadas à farmácia do hospital, de janeiro a setembro de 2009; com o auxílio de programas sobre IM, para categorizar IM de nível I e II. Resultados: Na análise 26,53% apresentaram IM, em que 23,64% foram classificadas em nível I e 76,35% em nível II. Dentre as IM com maior frequência no nível I, estavam: ácido acetilsalicílico (AAS) e clopidogrel, AAS e heparina, captopril e espironolactona, digoxina e hidroclorotiazida. Houve uma redução em percentual de IM de nível I, comparando janeiro representado por 26,5% e setembro representado por 18,4%. Já nas IM de nível II, tem-se as seguintes associações com maior frequência: AAS e propranolol, AAS e insulina regular humana, AAS e ate- nolol, AAS e enalapril, AAS e carvedilol. Conclusão: A atuação dos farmacêuticos cola- borou à redução de IM de nível I, devido à intervenção por meio de comunicação estabe- lecida com os prescritores; sinalizando a importância da equipe interprofissional em saúde.
Objective: To evaluate drug interactions (MI), in which risks outweigh the benefits (level I) or benefits outweigh the risks (level II); from the retrospective analysis of medical prescriptions in a University Hospital in the state of São Paulo, Brazil. Methods: 19,762 prescriptions destined to the hospital pharmacy were analyzed, from January to September 2009; with the help of programs on MI, to categorize level I and II MI. Results: In the analysis 26.53% presented MI, in which 23.64% were classified in level I and 76.35% in level II. Among the most frequent level I MI were: acetylsalicylic acid (ASA) and clopidogrel, ASA and heparin, captopril and spironolactone, digoxin and hydrochlorothiazide. There was a reduction in the percentage of level I MI, comparing January, which accounted for 26.5%, and September, which accounted for 18.4%. As for level II MI, the following associations were more frequent: ASA and propranolol, ASA and regular human insulin, ASA and atenolol, ASA and enalapril, ASA and carvedilol. Conclusion: The role of pharmacists collaborated to the reduction of level I MI, due to the intervention by means of communication established with the prescribers; signaling the importance of the interprofessional health team.
Objetivo: Evaluar las interacciones medicamentosas (IM), en las que los riesgos superan a los beneficios (nivel I) o los beneficios superan a los riesgos (nivel II); a partir del análisis retrospectivo de las prescripciones médicas en un Hospital Universitario del estado de São Paulo, Brasil. Métodos: Se analizaron 19.762 prescripciones destinadas a la farmacia del hospital, de enero a septiembre de 2009; con la ayuda de programas sobre IM, para categorizar los IM de nivel I y II. Resultados: En el análisis el 26,53% presentaron IM, en el que el 23,64% se clasificaron en nivel I y el 76,35% en nivel II. Entre los IM de nivel I más frecuentes estaban: ácido acetilsalicílico (AAS) y clopidogrel, AAS y heparina, captopril y espironolactona, digoxina e hidroclorotiazida. Hubo una reducción del porcentaje de IM de nivel I, comparando enero, que supuso el 26,5%, y septiembre, que supuso el 18,4%. En cuanto a los IM de nivel II, fueron más frecuentes las siguientes asociaciones: AAS y propranolol, AAS e insulina humana regular, AAS y atenolol, AAS y enalapril, AAS y carvedilol. Conclusiones: El papel de los farmacéuticos colaboró a la reducción de las IM de nivel I, debido a la intervención mediante la comunicación establecida con los prescriptores; señalando la importancia del equipo sanitario interprofesional.
Assuntos
Prescrições de Medicamentos , Interações Medicamentosas , Farmácia , Avaliação de Medicamentos , Educação Interprofissional , Pacientes InternadosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos de noviembre y diciembre de 2022 y enero de 2023, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento. (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from November 2022 to January of 2023, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product. (AU)
Assuntos
Humanos , Avaliação de Medicamentos/efeitos adversos , Avaliação de Medicamentos/tendências , Preparações Farmacêuticas , Aprovação de Drogas , Espanha , Europa (Continente)RESUMO
Objetivo: Evaluar la utilización en la práctica clínica de cuatro antibióticos de amplio espectro o innovadores: ceftolozano/tazobactam, ceftazidima/avibactam, ceftarolina y dalbavancina. Métodos: Estudio retrospectivo en que se han recogido datos de los pacientes que han recibido dichos antibióticos entre julio de 2018 y junio de 2019 en un hospital terciario. Se recogen las condiciones de uso y los resultados en efectividad a los 30 días para dalbavancina, y para el resto de antimicrobianos a los 3-5 días del inicio, a los 14 y a los 30 días para determinar mortalidad. Resultados: Se recogieron datos de 51 pacientes, con una mediana de edad de 63 años. La infección más comúnmente tratada fue neumonía (41,2%). Tres pacientes (5,9%) recibieron la terapia en estudio como primera línea y 43 (84,3%) recibieron antibióticos concomitantes. En el 66,7% de las infecciones se había aislado previamente un microorganismo sensible. En el 19,6% de los casos el cultivo fue negativo. En el grupo dalbavancina, el 75% de los pacientes se curaron a los 30 días. En el resto de antimicrobianos, el tratamiento resultó efectivo a los 3-5 días en el 65,1%. El 51,2% se curaron a los 14 días y un 30,2% fallecieron a los 30 días. Conclusiones: Los resultados de efectividad resultan comparables a estudios publicados con diseños similares. Se detecta la importancia de fomentar un uso adecuado de los antibióticos, como tratamientos dirigidos o empíricos en casos de riesgo de resistencias, priorizando su desescalada. Es esencial la implantación de equipos multidisciplinares PROA. (AU)
Objective: To evaluate the use in clinical practice of four recently marketed antibiotics: ceftolozane/tazobactam, ceftazidime/avibactam, ceftaroline, and dalbavancin. Methods: Retrospective study in which data have been collected from patients who have received these antibiotics between July 2018 and June 2019, in a third-level hospital. The conditions of use and the results in clinical efficacy measured in three periods have been studied: 3-5 days after the start of treatment, 14 days and 30 days to determine mortality. Results: Data were collected from a total of 51 patients, with a median age of 63 years. The most commonly treated infection was pneumonia (41.2%). Three patients (5.9%) received study therapy as the first line of treatment and 43 (84.3%) received concomitant antibiotics. In 66.7% of the infections, a sensitive microorganism to the antibiotic under study had been previously isolated. In 19.6% of the cases, the culture was negative. In the dalbavancin group, 75% of the pacients cured at day 30. In the other groups, the treatment was effective at 3-5 days in 65.1% of the cases. 51.2% experienced clinical cure at 14 days and 30.2% died at 30 days. Conclusions: The effectiveness results are comparable to published studies with similar designs. The importance of promoting an adequate use of antibiotics is detected, as directed or empirical treatments in cases of risk of resistance, prioritizing their de-escalation. The implementation of multidisciplinary PROA teams is essential. (AU)
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Resistência Microbiana a Medicamentos , Gestão de Antimicrobianos , Tazobactam/análogos & derivados , Ceftazidima/análogos & derivados , Avaliação de MedicamentosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en febrero, marzo y abril de 2023 considerados de mayor interés para los profesionales sanitarios. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento. (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency issued in February, March and April 2023, and considered of interest to healthcare professionals, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product. (AU)
Assuntos
Avaliação de Medicamentos , Preparações Farmacêuticas/análiseRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en febrero, marzo y abril de 2023 considerados de mayor interés para los profesionales sanitarios. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento. (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency issued in February, March and April 2023, and considered of interest to healthcare professionals, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product. (AU)
Assuntos
Avaliação de Medicamentos , Preparações Farmacêuticas/análiseRESUMO
El empoderamiento del paciente supone uno de los principales pilares dela humanización. Por ello, la consideración de las preferencias y expectativas de los pacientes debería ser tenida en cuenta durante el ejerciciode cualquiera de los profesionales de la salud. Mejorar la supervivenciaglobal y la calidad de vida son los deseos principales de los pacientes. Dehecho, la reciente aparición de los llamados Patient Reported Outcomes hasupuesto un importante foco para los agentes involucrados en la asistenciasanitaria. El farmacéutico hospitalario especializado en la evaluación demedicamentos es un profesional que evalúa la eficacia, seguridad, adecuación y eficiencia de los tratamientos prescritos por facultativos, y debebasar la toma de decisiones tanto en factores técnicos como en los cuatroprincipios bioéticos. La correcta aplicación de la práctica clínica basadaen la evidencia permite proveer a los pacientes de incrementos de supervivencia y/o calidad de vida, adecuando la conveniencia y costes a lasituación actual. Teniendo en cuenta esto, podría decirse que la evaluaciónde medicamentos supone un fuerte compromiso con la humanización. Porotra parte, las organizaciones que promueven la evaluación y selecciónde medicamentos rigurosamente se erigen como aliados de los pacientes,ya que repercuten de forma directa en éstos y de forma indirecta en lasociedad. Las agencias reguladoras encargadas de la aprobación y financiación de medicamentos en los sistemas sanitarios protagonizan un papelfundamental en el proceso de humanización de la toma de decisiones clínicas y empoderamiento de pacientes, ya que si aprueban el uso de nuevos medicamentos según datos que no miden la calidad de vida o supervivencia de los pacientes cuando ya existen otras alternativas terapéuticaspara estas patologías, indirectamente no estarán dando respuesta a lasexpectativas de los pacientes y conculcarán los principios bioéticos. (AU)
Patient empowerment is one of the main pillars of humanisation. Therefore,consideration of patients preferences and expectations should be takeninto account during the practice of any healthcare professional. Improvingoverall survival and quality of life are the main wishes of patients. Indeed,the recent emergence of Patient Reported Outcomes has become animportant focus for healthcare providers. The hospital pharmacist specialised in drug evaluation is a professional who evaluates the efficacy, safety,appropriateness and efficiency of treatments prescribed by physicians,and decision-making must be based on both technical factors and thefour principles of bioethics. The correct application of evidence-based clinical practice allows to provide patients with increases in survival and/orquality of life, adapting the convenience and costs to the current situation.With this in mind, it could be said that the evaluation of medicines involvesa strong commitment to humanisation. On the other hand, organisationsthat promote the rigorous evaluation and selection of medicines standas allies of patients, as they have a direct impact on them and an indirect impact on society. Regulatory agencies in charge of approving andfinancing medicines in healthcare systems play a key role in the processof humanising clinical decision-making and empowering patients. If theseagencies approve the use of new medicines based on data that do notmeasure quality of life or survival of patients when there are already othertherapeutic alternatives for these pathologies, they are indirectly failing tomeet patients expectations and are infringing bioethical principles. (AU)
Assuntos
Humanos , Farmácia , Assistência Centrada no Paciente , Bioética , Medicina Baseada em Evidências , Avaliação de Medicamentos , Poder PsicológicoRESUMO
Introdução: O Brasil, assim como outros países, vem alterando seu perfil demográfico elevando o número de pessoas idosas, o que repercute em mudanças não só para sociedade, mas também para saúde pública. Este grupo de pacientes é mais vulnerável devido à fisiologia inerente ao envelhecimento, logo se tornam mais propensos ao uso de medicamentos que podem causar outros problemas de saúde. Essa probabilidade de risco é uma preocupação atual e levou a criação de métodos que norteiam os prescritores para adequarem suas terapêuticas neste grupo de pacientes. Um destes métodos é o critério de Beers, que é atualizado periodicamente trazendo uma lista de medicamentos potencialmente inapropriados (MPIs) para idosos. Objetivo: Avaliar a prescrição de pacientes idosos internados no Hospital Universitário da Universidade Federal de Juiz de Fora (HU-UFJF/Ebserh) quanto à prevalência do uso de MPI e polifarmácia, no período de julho a agosto de 2019. Material e Métodos: Estudo observacional descritivo e retrospectivo, cujos dados foram coletados de prontuários pacientes idosos com idade igual ou superior a 65 anos para obtenção dos resultados que foram avaliados estatisticamente. Resultados: Foram avaliados 187 prontuários, e observada prevalência de 80,2% da prescrição de MPIs, sendo os mais prevalentes omeprazol e benzodiazepínicos. A maioria dos pacientes tiveram polifarmácia (95,7%). Conclusão: Os resultados convergem com base no critério de Beers, para necessidade de adequar a terapia de pacientes idosos. É necessário também avaliar os benefícios e alternativas quanto aos MPIs mais prevalentes, além de realizar estudos observacionais sobre possíveis efeitos adversos que possam ser consequência do uso desses medicamentos, com objetivo de aperfeiçoar a terapia farmacológica e aprimorar a farmacoeconomia, melhorando assim a qualidade de vida dos pacientes idosos.
Introduction: Brazil, like other countries, has been changing its demographic profile, increasing the number of elderly people, which reflects in changes not only for society, but also for public health. This group of patients is more vulnerable due to the inherent physiology of aging, so they become more likely to use medications that can cause other health problems. This risk probability is a current concern and has led to the creation of methods that guide prescribers to adapt their therapies in this group of patients. One of these methods is the Beers criterion, which is periodically updated with a list of potentially inappropriate medications (PIM) for the elderly. Objective: To evaluate the prescription of elderly patients hospitalized at the University Hospital of Juiz de Fora (HU-UFJF/Ebserh) regarding the prevalence of the use of PIM and polypharmacy, from July to August 2019. Material and Methods: Descriptive and retrospective observational study, whose data were collected from medical records of elderly patients aged 65 years or older to obtain the results that were statistically evaluated. Results: A total of 187 medical records were evaluated, and a prevalence of 80.2% of the prescription of PIMs was observed, the most prevalent being omeprazol and benzodiazepines. Most patients had polypharmacy (95.7%). Conclusion: The results converge, based on the Beers criterion, for the need to suit the therapy of elderly patients. It is also necessary to evaluate the benefits and alternatives regarding the most prevalent PIMs, in addition to conducting observational studies on possible adverse effects that may be a consequence of the use of these medications, aiming to refine pharmacological therapy and improve pharmacoeconomics, thus improving quality of life of elderly patients.
Assuntos
Prescrições de Medicamentos , Envelhecimento , Saúde do Idoso , Polimedicação , Avaliação de Medicamentos , Tratamento Farmacológico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Uso de Medicamentos , Lista de Medicamentos Potencialmente Inapropriados , HospitalizaçãoRESUMO
Abstract he aim of this work was to develop an oral solution of captopril at 5 mg/mL preservative-free. Two formulations were prepared, one containing sweetener (formulation 1) and the other without this excipient (formulation 2). The results found of validation parameters from analytical method performed by HPLC for captopril were, linearity 0.9998, the limit of detection 15.71 µg/mL, the limit of quantification 47.60 µg/mL, repeatability 1.05%, intermediate precision 2.42%, accuracy intraday 101,53%, accuracy inter-day 99.85%. Moreover, the results found for captopril disulfide were, linearity 0.9999, limit of detection 0.65 µg/mL, limit of quantification 1.96 µg/mL, repeatability 2.28%, intermediate precision 1.51%, accuracy intraday 101.36%, accuracy inter-day 100.29%. The appearance of formulations was clear and colorless, pH measures were 3.12 and 3.04, dosage of captopril and captopril disulfide were 99.45% and 99.82%, 0.24% and 0.12% for formulation 1 and formulation 2, respectively. The stability study demonstrated that the concentration of captopril and captopril disulfide in the formulations was > 90% and below 3%, respectively. The in vivo palatability study in animals and humans showed that Formulation 1 containing the sweetener had better acceptance. Thus, the sweetener was able to improve the unpleasant taste of the formulation
Assuntos
Pediatria/classificação , Captopril/análise , Química Farmacêutica/classificação , Estabilidade de Medicamentos , Conservantes Farmacêuticos/farmacologia , Edulcorantes , Paladar , Cromatografia Líquida de Alta Pressão/métodos , Avaliação de MedicamentosRESUMO
El dolor lumbar bajo y el dolor cervical con o sin irradiación son causas muy comunes de consulta a los médicos generalistas en los países desarrollados. La discopatía aguda y el dolor por estenosis del canal espinal son los diagnósticos más frecuentes. La postura tradicional ha sido la de administrar antiinflamatorios no esteroideos (AINES) para estas lumbalgias o cervicalgias agudas. Cuando existe irradiación neural por compresión radicular es usual asociar al AINE un corticoide a baja dosis, así como un antineurítico, para lograr un mejor resultado. Con el objeto de documentar la utilidad de esta práctica habitual, efectuamos en 142 pacientes ambulatorios un estudio multicéntrico randomizado que compara la efectividad y la tolerancia de una asociación a dosis fija de diclofenac, betametasona y cianocobalamina administrada por vía oral versus la administración de diclofenac como monofármaco en el tratamiento de la patología dolorosa de la columna lumbar y cervical asociada a compresión neural. La asociación demostró ser más eficaz en controlar el dolor y mejorar la funcionalidad de los pacientes que la administración de diclofenac en forma aislada y se asoció a escasos efectos colaterales, principalmente digestivos
Low back pain and neck pain with or without radiation are very common causes of consultation with general practitioners in developed countries. Acute discopathy and pain due to spinal canal stenosis are the most frequent diagnoses. The traditional approach has been to administer non-steroidal antiinflammatory drugs (NSAIDs) for these acute low back or cervical pain. When there is neural radiation due to root compression, it is usual to associate a low-dose corticosteroid with the NSAID, as well as an antineuritic, to achieve a better result. In order to document the usefulness of this routine practice, we conducted a randomized multicenter study in 142 outpatients that compared the effectiveness and tolerance of a fixed-dose combination of diclofenac, betamethasone, and cyanocobalamin administered orally versus the administration of diclofenac as Monopharmaceutical in the treatment of painful pathology of the lumbar and cervical spine associated with neural compression. The association proved to be more effective in controlling pain and improving the functionality of patients than the administration of diclofenac in isolation and was associated with few side effects, mainly digestive
Assuntos
Humanos , Adulto , Pessoa de Meia-Idade , Gatos , Estenose Espinal/terapia , Vitamina B 12/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Diclofenaco/administração & dosagem , Administração Oral , Resultado do Tratamento , Dor Lombar/tratamento farmacológico , Cervicalgia/tratamento farmacológico , Combinação de Medicamentos , Avaliação de MedicamentosRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en octubre, noviembre y diciembre de 2019, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in October, November and December of 2019, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Humanos , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Avaliação de Medicamentos/métodos , Pessoal de Saúde/normas , Ensaios Clínicos como Assunto , Resultado do Tratamento , Avaliação de Medicamentos/estatística & dados numéricos , Agências Internacionais/normas , Bulas de Medicamentos , Anticorpos Monoclonais , Ofloxacino , Ketamina , Glucagon , Imipenem , Estimulantes do Sistema Nervoso Central , Vacinas contra EbolaRESUMO
La terapia celular adoptiva está revolucionando el panorama de la terapéutica actual. La gestión de los medicamentos CAR-T supone un reto para el sistema nacional de salud (SNS), pues se trata de medicamentos complejos de un elevado impacto sanitario. En esta línea, la elaboración de protocolos fármaco-clínicos con criterios claramente definidos ayudará a un correcto posicionamiento y selección de los pacientes candidatos a estas terapias. Así mismo, la administración de estos fármacos debe realizarse en centros previamente seleccionados y cualificados para tal fin, garantizando la equidad en el acceso. Por otro lado, es prioritario un abordaje multidisciplinar de todos los pacientes que sean tratados con las terapias CAR-T. Finalmente es fundamental la evaluación y el registro constante de resultados, los cuales contribuirán a determinar el beneficio real de la terapia, reclamando la necesidad de precios equitativos para garantizar la sostenibilidad del SNS y el acceso a los pacientes previamente seleccionados
Adoptive cell therapy is revolutionizing the current therapeutic landscape. The management of CAR-T drugs is a challenge for The National Health System (NHS), as they are complex drugs with high impact on health. This way, the development of clinical pharmaceutical protocols with clearly defined criteria, will help in correct positioning and selection of patients candidates for these therapies. Likewise, administration of these drugs must be carried out in centers previously selected and qualified for this purpose, guaranteeing equity of access. On the other hand, a multidisciplinary approach of all patients treated with CAR-T therapies is a priority. Finally, the assessment and the constant result recording are essencial, since they will contribute to determining the real benefit of these therapies, claiming the need for equitable prices, guaranteeing the sustainability of the NHS and the access of previously selected patients to them
Assuntos
Humanos , Imunoterapia Adotiva/métodos , Receptores de Antígenos Quiméricos/uso terapêutico , Legislação de Medicamentos , Receptores de Antígenos de Linfócitos T/uso terapêutico , Antígenos CD19/uso terapêutico , Avaliação de MedicamentosRESUMO
El siguiente trabajo tiene como objetivos clasificar los ingredientes farmacéuticos activos (IFAs) de los sólidos orales de liberación inmediata del Cuadro Básico de Medicamentos de Cuba (CBM) que son producidos nacionalmente, según el Sistema de Clasificación Biofarmacéutica (SCB), y proponer aquellos que podrían demostrar su intercambiabilidad terapéutica a través de ensayos de disolución in vitro. Para ello se utilizó el listado de medicamentos del CBM de Cuba del 2019 y se realiza una clasificación biofarmacéutica provisional consenso, a partir de diferentes clasificaciones biofarmacéuticas publicadas y de una extensiva revisión de la literatura. Se identificó que aproximadamente el 48% de los IFAs del CBM presentan polimorfismo y que el 12,3% de las formas sólidas orales del CBM de Cuba tienen un estrecho margen terapéutico, por lo que no pueden ser bioexonerados mediante estudios de bioequivalencia in vitro basados en el SCB. Se constató que un 50,8% de los IFAs de formas sólidas orales de liberación inmediata del CBM de Cuba han sido clasificados según el SCB por la OMS. La aplicación conjunta de diversas metodologías de clasificación biofarmacéutica permitió clasificar provisionalmente todos los IFAs de las formas sólidas orales del CBM, demostrando que el 66,1% pertenece a las clases I, III y I/III del SCB, por lo que podrían ser bioexonerados de ensayos de bioequivalencia in vivo en humanos
The goals of the present work are to classify the active pharmaceutical ingredients (APIs) of the oral solids of immediate release of the Essential List of Medicines of Cuba (CBM) that are produced nationally, according to the Biopharmaceutical Classification System (BCS), and to propose those that could demonstrate their therapeutic interchangeability through in vitro dissolution tests. For this was used the Cuban CBM drug list of 2019, and a provisional consensus biopharmaceutical classification is proposed, based on different published biopharmaceutical classifications and an extensive review of the literature. It was identified that approximately 48% of the CBM IFAs present polymorphism and that 12.3% of the oral solid forms of CBM in Cuba have a narrow therapeutic margin, for which reason they cannot be bioexonerated through in vitro bioequivalence studies based on BCS. It was found that 50.8% of the oral solid forms of CBM in Cuba have been classified according to SCB by WHO. The joint application of diverse methodologies of biopharmaceutical classification allowed to provisionally classify all the IFAs of the oral solid forms of CBM, demonstrating that 66.1% belongs to classes I, III and I/III of the SCB, reason why they could be biowaivered from in vivo bioequivalence assays in humans
Assuntos
Preparações Farmacêuticas/classificação , Biofarmácia/normas , Equivalência Terapêutica , Medicamentos Essenciais/classificação , Preparações Farmacêuticas/química , Medicamentos Essenciais/química , Medicamentos Essenciais/normas , Padrões de Referência , Cuba , Avaliação de Medicamentos , Solubilidade , Técnicas In VitroRESUMO
La inmunoterapia ha revolucionado la terapéutica del cáncer en los últimos años y sigue siendo el objetivo principal de numerosas líneas de investigación. Los inhibidores de puntos de control inmunitario (ICIs) son una alternativa muy atractiva para clínicos y pacientes porque han conseguido alcanzar mejores tasas de respuesta y de supervivencia a largo plazo. Además, presentan un buen perfil de tolerancia frente a la terapia oral y los eventos adversos relacionados con la inmunoterapia (irAE) en muy pocos casos causan una morbilidad destacable y la mayoría de pacientes disfruta de una excelente calidad de vida con síntomas mínimos durante el tratamiento. Sin embargo, existe una gran brecha en el conocimiento sobre la seguridad y la efectividad de estos fármacos en algunos tipos de pacientes que por sus características suelen ser excluidos de los ensayos clínicos, resultando difícil inferir los resultados a este tipo de pacientes. Se trata de aquellos pacientes con un sistema inmunológico exacerbado (pacientes con enfermedades autoinmunes) o comprometido (pacientes que han sido sometidos a trasplante hematológico o de órgano sólido o pacientes con infecciones virales crónicas). El objetivo de esta revisión es describir la experiencia del uso de ICIs en este tipo de pacientes y ofrecer al lector, de manera resumida, algunos aspectos clave con el fin de motivar su interés por la investigación en este campo
In recent years, immunotherapy has revolutionized the treatment of cancer and remains the main objective of many lines of research. Immune checkpoint inhibitors (ICIs) are a very attractive alternative treatment because they have been achieved better response rates and long-term survival rates in several types of cancer. Furthermore, ICIs have favorable tolerance profiles and immune related adverse events (irAEs) do not usually result in significant morbidity and most patients enjoy an excellent quality of life with minimal symptoms during treatment. However, there is a gap in knowledge on the safety and effectiveness of ICIs in patients who are often excluded from clinical trials due to their characteristics, making it difficult to infer the results of clinical trials to these patients. They are patients with autoimmune diseases or with a compromised immune system (solid organ/hematological transplant patients or with chronic viral infections). The aim of this review is to extend current knowledge of the use of ICIs in these patients, in clinical practice and to propose new research topics